Zhenling Guo

发表

The role of allogeneic haematopoietic cell transplantation as consolidation after anti-CD19 CAR-T cell therapy in adults with relapsed/refractory acute lymphoblastic leukaemia: a prospective cohort study

S. Tu, Jilong Yang, Xuan Zhou, 2022, Bone Marrow Transplantation.

Shortening the ex vivo culture of CD19‐specific CAR T‐cells retains potent efficacy against acute lymphoblastic leukemia without CAR T‐cell‐related encephalopathy syndrome or severe cytokine release syndrome

S. Tu, Lung-Ji Chang, Jilong Yang, 2019, American journal of hematology.

CD19 and CD70 Dual-Target Chimeric Antigen Receptor T-Cell Therapy for the Treatment of Relapsed and Refractory Primary Central Nervous System Diffuse Large B-Cell Lymphoma

S. Tu, Lung-Ji Chang, Xuan Zhou, 2019, Front. Oncol..

Preclinical and clinical advances in dual‐target chimeric antigen receptor therapy for hematological malignancies

S. Tu, Xuan Zhou, Yanjie He, 2021, Cancer science.

Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas

S. Tu, Lung-Ji Chang, Jilong Yang, 2020, Frontiers in Immunology.

Mechanisms underlying CD19-positive ALL relapse after anti-CD19 CAR T cell therapy and associated strategies

S. Tu, Xuan Zhou, Meifang Li, 2020, Biomarker Research.

Mechanisms underlying CD19-positive ALL relapse after anti-CD19 CAR T cell therapy and associated strategies

S. Tu, Xuan Zhou, Meifang Li, 2020, Biomarker Research.

A Novel Chimeric Antigen Receptor T Cells Therapy Strategy That Dual Targeting CD19 and CD123 to Treat Relapsed Acute Lymphoblastic Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation

S. Tu, Lung-Ji Chang, Jilong Yang, 2018, Blood.